BRPI0716749A2 - Compostos pirido (2,3-d) pirimidinona e seu uso como inibidores pi3 - Google Patents

Compostos pirido (2,3-d) pirimidinona e seu uso como inibidores pi3

Info

Publication number: BRPI0716749A2
Authority: BR; Brazil
Prior art keywords: pyrid; inhibitors; pyrimidinone compounds; pyrimidinone; compounds
Prior art date: 2006-09-15

Application number

BRPI0716749-0A2A

Other languages

English (en)

Inventor

Hengmiao Cheng

Dilip Bhumralkar

Klaus Ruprecht Dress

Jacqui Elizabeth Hoffman

Mary Catherine Johnson

Robert Steven Kania

Phuong Thi Quy Le

Mitchell David Nambu

Mason Alan Pairish

Michael Bruno Plewe

Khanh Tuan Tran

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-15

Filing date

2007-09-03

Publication date

2014-02-18

2007-09-03 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2014-02-18 Publication of BRPI0716749A2 publication Critical patent/BRPI0716749A2/pt

2020-10-06 Publication of BRPI0716749B1 publication Critical patent/BRPI0716749B1/pt

2021-05-25 Publication of BRPI0716749B8 publication Critical patent/BRPI0716749B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyridine Compounds (AREA)

BRPI0716749A 2006-09-15 2007-09-03 compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende BRPI0716749B8 (pt)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US84506506P	2006-09-15	2006-09-15
US60/845,065		2006-09-15
US94785207P	2007-07-03	2007-07-03
US60/947,852		2007-07-03
US95262807P	2007-07-30	2007-07-30
US60/952,628		2007-07-30
PCT/IB2007/002578 WO2008032162A1 (en)	2006-09-15	2007-09-03	Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (3)

Publication Number	Publication Date
BRPI0716749A2 true BRPI0716749A2 (pt)	2014-02-18
BRPI0716749B1 BRPI0716749B1 (pt)	2020-10-06
BRPI0716749B8 BRPI0716749B8 (pt)	2021-05-25

Family

ID=38859750

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0716749A BRPI0716749B8 (pt)	2006-09-15	2007-09-03	compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende

Country Status (42)

Country	Link
US (3)	US7696213B2 (pt)
EP (1)	EP2074122B9 (pt)
JP (1)	JP4718637B2 (pt)
KR (1)	KR101099926B1 (pt)
CN (1)	CN101573358B (pt)
AP (1)	AP2710A (pt)
AR (1)	AR062785A1 (pt)
AT (1)	ATE514695T1 (pt)
AU (1)	AU2007297212B8 (pt)
BR (1)	BRPI0716749B8 (pt)
CA (1)	CA2663401C (pt)
CL (1)	CL2007002682A1 (pt)
CR (1)	CR10662A (pt)
CU (1)	CU23783B7 (pt)
CY (1)	CY1111911T1 (pt)
DK (1)	DK2074122T5 (pt)
DO (1)	DOP2009000039A (pt)
EA (1)	EA016388B1 (pt)
ES (1)	ES2366489T3 (pt)
GE (1)	GEP20115306B (pt)
GT (1)	GT200700077A (pt)
HK (1)	HK1138589A1 (pt)
HN (1)	HN2007000267A (pt)
HR (1)	HRP20110621T2 (pt)
IL (1)	IL197243A (pt)
MA (1)	MA30709B1 (pt)
ME (1)	MEP8009A (pt)
MX (1)	MX2009002927A (pt)
MY (1)	MY146420A (pt)
NI (1)	NI200900032A (pt)
NO (1)	NO342357B1 (pt)
NZ (1)	NZ575167A (pt)
PE (1)	PE20080670A1 (pt)
PL (1)	PL2074122T3 (pt)
PT (1)	PT2074122E (pt)
RS (2)	RS51927B (pt)
SI (1)	SI2074122T1 (pt)
TN (1)	TN2009000085A1 (pt)
TW (1)	TWI334353B (pt)
UY (1)	UY30588A1 (pt)
WO (1)	WO2008032162A1 (pt)
ZA (1)	ZA200901477B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2366489T3 (es) *	2006-09-15	2011-10-20	Pfizer Products Inc.	Compuesto de pirido (2,3-d) piridinona y sus uso como inhibidores de pi3.
SI2139484T1 (sl) *	2007-04-10	2013-10-30	Exelixis, Inc.	Postopki za zdravljenje raka s pirido pirimidin PI3K alfa inhibitorji
CA2683820A1 (en) *	2007-04-11	2008-10-23	Exelixis, Inc.	Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
US20110105521A1 (en) *	2008-07-11	2011-05-05	Novartis Ag	Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
JP5674661B2 (ja)	2008-08-20	2015-02-25	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
AR072938A1 (es)	2008-08-20	2010-09-29	Southern Res Inst	Derivados de piridina y pirimidina azosustituidos y su uso en el tratamiento de infecciones virales
US8697694B2 (en)	2008-08-20	2014-04-15	Merck Sharp & Dohme Corp.	Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020238A (en)	2008-08-20	2010-06-01	Schering Corp	Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010039740A1 (en) *	2008-09-30	2010-04-08	Exelixis, Inc.	PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
US10010439B2 (en)	2010-06-13	2018-07-03	Synerz Medical, Inc.	Intragastric device for treating obesity
US10420665B2 (en)	2010-06-13	2019-09-24	W. L. Gore & Associates, Inc.	Intragastric device for treating obesity
US8628554B2 (en)	2010-06-13	2014-01-14	Virender K. Sharma	Intragastric device for treating obesity
US9526648B2 (en)	2010-06-13	2016-12-27	Synerz Medical, Inc.	Intragastric device for treating obesity
NZ609448A (en)	2010-12-16	2015-07-31	Hoffmann La Roche	Tricyclic pi3k inhibitor compounds and methods of use
US8664230B2 (en) *	2011-03-17	2014-03-04	The Asan Foundation	Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) *	2011-06-15	2013-02-16	Exelixis Inc	使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
US9675595B2 (en)	2011-08-31	2017-06-13	Novartis Ag	Synergistic combinations of PI3K- and MEK-inhibitors
CN104829609B (zh) *	2014-02-11	2016-08-03	北大方正集团有限公司	取代的吡啶并嘧啶化合物及其制备方法和应用
US9828373B2 (en)	2014-07-26	2017-11-28	Sunshine Lake Pharma Co., Ltd.	2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
CN105330699B (zh) *	2014-08-13	2018-12-04	山东汇睿迪生物技术有限公司	一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
KR20170058432A (ko)	2014-10-10	2017-05-26	화이자 인코포레이티드	상승 효과적 아우리스타틴 조합
EP3302565B1 (en)	2015-06-04	2019-11-06	Pfizer Inc	Solid dosage forms of palbociclib
US10779980B2 (en)	2016-04-27	2020-09-22	Synerz Medical, Inc.	Intragastric device for treating obesity
ES2922898T3 (es)	2016-07-06	2022-09-21	Univ Michigan Regents	Inhibidores multifuncionales de las rutas biológicas de MEK/PI3K y mTOR/MEK/PI3K y métodos terapéuticos que usan los mismos
EP3497103B1 (en)	2016-08-15	2021-05-05	Pfizer Inc.	Pyridopyrimdinone cdk2/4/6 inhibitors
US11241500B2 (en) *	2016-12-14	2022-02-08	Tarveda Therapeutics, Inc.	HSP90-targeting conjugates and formulations thereof
US10596165B2 (en)	2018-02-12	2020-03-24	resTORbio, Inc.	Combination therapies
EA202092692A1 (ru)	2018-06-15	2021-04-21	Навитор Фармасьютикалз, Инк.	Аналоги рапамицина и их применения
CA3124574A1 (en) *	2018-12-28	2020-07-02	Spv Therapeutics Inc.	Cyclin-dependent kinase inhibitors
WO2020140053A1 (en) *	2018-12-28	2020-07-02	Spv Therapeutics Inc.	Cyclin-dependent kinase inhibitors
US11583538B2 (en)	2019-04-08	2023-02-21	Venenum Biodesign, LLC	Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
CA3163680A1 (en)	2019-12-05	2021-06-10	David John O'neill	Rapamycin analogs and uses thereof
CN114901664B (zh) *	2020-01-10	2024-07-02	南京再明医药有限公司	吡啶酮化合物及应用
WO2022075974A1 (en) *	2020-10-06	2022-04-14	Venenum Biodesign, LLC	Cyclic trex1 inhibitors
CA3198943A1 (en)	2020-11-18	2022-05-27	Daniel L. Flynn	Gcn2 and perk kinase inhibitors and methods of use thereof
AU2022389984A1 (en) *	2021-11-18	2024-06-13	Traws Pharma, Inc.	Methods and compositions for treating cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5264437A (en) *	1992-03-20	1993-11-23	Syntex (U.S.A.) Inc.	Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
GEP20012444B (en)	1994-11-14	2001-05-25	Warner Lambert Company Us	6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation
CN1177960A (zh) *	1995-03-10	1998-04-01	圣诺菲药品有限公司	6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en)	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en)	1997-02-04	1999-07-20	Sepracor Inc.	Synthesis of terfenadine and derivatives
US6498163B1 (en)	1997-02-05	2002-12-24	Warner-Lambert Company	Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
AU749750B2 (en)	1997-02-05	2002-07-04	Warner-Lambert Company	Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en)	1999-03-04	1999-04-28	Glaxo Group Ltd	Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
HUP0203803A3 (en)	2000-01-27	2004-09-28	Warner Lambert Co	Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
NZ520962A (en)	2000-03-06	2003-09-26	Warner Lambert Co	5-alkylpyrido[2,3-d]pyrimidines cyclin-dependent tyrosine kinase inhibitors
EP1277738B1 (en)	2000-04-27	2011-03-30	Astellas Pharma Inc.	Condensed heteroaryl derivatives
EP1364950A4 (en)	2001-02-26	2005-03-09	Tanabe Seiyaku Co	PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
US7019002B2 (en) *	2001-12-11	2006-03-28	Pharmacia & Upjohn, S.P.A.	Pyridopyrimidinones derivatives as telomerase inhibitors
CA2473026C (en)	2002-01-22	2011-05-03	Warner-Lambert Company Llc	2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
JP2003321472A (ja)	2002-02-26	2003-11-11	Takeda Chem Ind Ltd	Ｇｒｋ阻害剤
ATE370952T1 (de)	2002-04-19	2007-09-15	Smithkline Beecham Corp	Neue verbindungen
US20040063658A1 (en)	2002-05-06	2004-04-01	Roberts Christopher Don	Nucleoside derivatives for treating hepatitis C virus infection
JP2004083587A (ja)	2002-08-06	2004-03-18	Tanabe Seiyaku Co Ltd	医薬組成物
US7098332B2 (en)	2002-12-20	2006-08-29	Hoffmann-La Roche Inc.	5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja)	2002-12-24	2004-07-22	Pfizer Inc	置換６，６−ヘテロ二環式誘導体
US20050009849A1 (en)	2003-01-03	2005-01-13	Veach Darren R.	Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en)	2003-04-02	2004-10-21	Imclone Systems Incorporated	4-fluoroquinolone derivatives and their use as kinase inhibitors
JP2007504283A (ja)	2003-05-20	2007-03-01	ザリージェンツオブザユニバーシティオブカリフォルニア	β−アミロイド斑に作用物質を結合させる方法
MXPA06000484A (es)	2003-07-11	2006-04-05	Warner Lambert Co	Sal de isetionato de un inhibidor selectivo de la quinasa 4 dependiente de ciclina.
JP2006528193A (ja)	2003-07-22	2006-12-14	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｃ−ｆｍｓキナーゼの阻害剤としてのキノリノン誘導体
US7160888B2 (en)	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
PT1713806E (pt)	2004-02-14	2013-08-27	Irm Llc	Compostos e composições como inibidores da proteína quinase
EP1718645A1 (en)	2004-02-18	2006-11-08	Warner-Lambert Company LLC	2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
EP1740184A1 (en)	2004-03-30	2007-01-10	Pfizer Products Incorporated	Combinations of signal transduction inhibitors
WO2005105097A2 (en)	2004-04-28	2005-11-10	Gpc Biotech Ag	Pyridopyrimidines for treating inflammatory and other diseases
BRPI0510560A (pt) *	2004-05-04	2007-11-20	Warner Lambert Co	pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
EP1761281A1 (en)	2004-06-04	2007-03-14	Pfizer Products Incorporated	Method for treating abnormal cell growth
CA2575804A1 (en)	2004-08-26	2006-03-02	Boehringer Ingelheim International Gmbh	Pteridinones used as plk (polo like kinase) inhibitors
EP1807440B1 (en)	2004-11-03	2020-02-19	The University of Kansas	Novobiocin analogues as anticancer agents
EP1828186A1 (en)	2004-12-13	2007-09-05	Sunesis Pharmaceuticals, Inc.	Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en)	2004-12-23	2006-06-29	Pfizer Inc	C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
CA2623770C (en) *	2005-10-07	2014-05-27	Exelixis, Inc.	Pyridopyrimidinone inhibitors of pi3k.alpha.
US8247408B2 (en) *	2005-10-07	2012-08-21	Exelixis, Inc.	Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
EP1872922A1 (en) *	2006-06-27	2008-01-02	Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO	Method and apparatus for manufacturing a polymeric article
CA2658725A1 (en)	2006-08-16	2008-02-21	Exelixis, Inc.	Using pi3k and mek modulators in treatments of cancer
ES2366489T3 (es)	2006-09-15	2011-10-20	Pfizer Products Inc.	Compuesto de pirido (2,3-d) piridinona y sus uso como inhibidores de pi3.
AU2008224941C1 (en) *	2007-03-14	2013-06-27	Exelixis Patent Company Llc	Inhibitors of the hedgehog pathway
CA2683820A1 (en)	2007-04-11	2008-10-23	Exelixis, Inc.	Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
WO2010039740A1 (en)	2008-09-30	2010-04-08	Exelixis, Inc.	PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
AU2011239537A1 (en) *	2010-04-16	2012-11-15	Curis, Inc.	Treatment of cancers having K-ras mutations

2007
- 2007-09-03 ES ES07804890T patent/ES2366489T3/es active Active
- 2007-09-03 BR BRPI0716749A patent/BRPI0716749B8/pt not_active IP Right Cessation
- 2007-09-03 AT AT07804890T patent/ATE514695T1/de active
- 2007-09-03 MX MX2009002927A patent/MX2009002927A/es active IP Right Grant
- 2007-09-03 SI SI200730715T patent/SI2074122T1/sl unknown
- 2007-09-03 RS RS20110379A patent/RS51927B/en unknown
- 2007-09-03 AP AP2009004790A patent/AP2710A/xx active
- 2007-09-03 NZ NZ575167A patent/NZ575167A/en not_active IP Right Cessation
- 2007-09-03 PL PL07804890T patent/PL2074122T3/pl unknown
- 2007-09-03 CN CN2007800342100A patent/CN101573358B/zh not_active Expired - Fee Related
- 2007-09-03 MY MYPI20091013A patent/MY146420A/en unknown
- 2007-09-03 AU AU2007297212A patent/AU2007297212B8/en not_active Ceased
- 2007-09-03 PT PT07804890T patent/PT2074122E/pt unknown
- 2007-09-03 RS RSP-2009/0104A patent/RS20090104A/sr unknown
- 2007-09-03 EA EA200970207A patent/EA016388B1/ru not_active IP Right Cessation
- 2007-09-03 ME MEP-80/09A patent/MEP8009A/xx unknown
- 2007-09-03 EP EP07804890.7A patent/EP2074122B9/en active Active
- 2007-09-03 WO PCT/IB2007/002578 patent/WO2008032162A1/en active Application Filing
- 2007-09-03 DK DK07804890.7T patent/DK2074122T5/da active
- 2007-09-03 CA CA2663401A patent/CA2663401C/en not_active Expired - Fee Related
- 2007-09-03 KR KR1020097005342A patent/KR101099926B1/ko active IP Right Grant
- 2007-09-03 GE GEAP200711157A patent/GEP20115306B/en unknown
- 2007-09-03 JP JP2009527908A patent/JP4718637B2/ja active Active
- 2007-09-12 UY UY30588A patent/UY30588A1/es not_active Application Discontinuation
- 2007-09-13 PE PE2007001238A patent/PE20080670A1/es not_active Application Discontinuation
- 2007-09-13 AR ARP070104059A patent/AR062785A1/es not_active Application Discontinuation
- 2007-09-13 GT GT200700077A patent/GT200700077A/es unknown
- 2007-09-13 US US11/854,999 patent/US7696213B2/en not_active Expired - Fee Related
- 2007-09-14 TW TW096134605A patent/TWI334353B/zh not_active IP Right Cessation
- 2007-09-14 CL CL200702682A patent/CL2007002682A1/es unknown
- 2007-09-17 HN HN2007000267A patent/HN2007000267A/es unknown
2009
- 2009-02-25 IL IL197243A patent/IL197243A/en active IP Right Grant
- 2009-03-02 ZA ZA200901477A patent/ZA200901477B/xx unknown
- 2009-03-11 DO DO2009000039A patent/DOP2009000039A/es unknown
- 2009-03-13 CR CR10662A patent/CR10662A/es unknown
- 2009-03-13 TN TN2009000085A patent/TN2009000085A1/fr unknown
- 2009-03-13 CU CU20090040A patent/CU23783B7/es not_active IP Right Cessation
- 2009-03-13 NI NI200900032A patent/NI200900032A/es unknown
- 2009-03-13 MA MA31707A patent/MA30709B1/fr unknown
- 2009-03-18 NO NO20091141A patent/NO342357B1/no not_active IP Right Cessation
2010
- 2010-02-09 US US12/702,937 patent/US8273755B2/en not_active Expired - Fee Related
- 2010-05-03 HK HK10104328.3A patent/HK1138589A1/xx not_active IP Right Cessation
2011
- 2011-07-20 CY CY20111100714T patent/CY1111911T1/el unknown
- 2011-08-24 HR HRP20110621TT patent/HRP20110621T2/hr unknown
2012
- 2012-08-16 US US13/587,825 patent/US8633204B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2366489T3 (es)	2011-10-20
MA30709B1 (fr)	2009-09-01
EP2074122B9 (en)	2013-09-11
TW200820972A (en)	2008-05-16
PE20080670A1 (es)	2008-06-14
AU2007297212A1 (en)	2008-03-20
TN2009000085A1 (fr)	2010-08-19
MX2009002927A (es)	2009-03-31
GEP20115306B (pt)	2011-10-10
US20100137279A1 (en)	2010-06-03
NO342357B1 (no)	2018-05-14
IL197243A (en)	2013-07-31
HN2007000267A (es)	2011-02-25
ES2366489T9 (es)	2013-12-27
CN101573358A (zh)	2009-11-04
US8273755B2 (en)	2012-09-25
CY1111911T1 (el)	2015-11-04
AP2710A (en)	2013-07-30
CU23783B7 (es)	2012-02-15
NO20091141L (no)	2009-03-31
PT2074122E (pt)	2011-08-24
KR101099926B1 (ko)	2011-12-28
CL2007002682A1 (es)	2008-04-04
US7696213B2 (en)	2010-04-13
EA200970207A1 (ru)	2009-08-28
PL2074122T3 (pl)	2011-10-31
ATE514695T1 (de)	2011-07-15
CN101573358B (zh)	2012-05-30
US20080090801A1 (en)	2008-04-17
MEP8009A (en)	2011-12-20
JP4718637B2 (ja)	2011-07-06
HRP20110621T1 (en)	2011-09-30
NZ575167A (en)	2010-10-29
NI200900032A (es)	2010-05-14
ZA200901477B (en)	2010-07-28
US20120309775A1 (en)	2012-12-06
DK2074122T5 (da)	2014-03-17
AU2007297212B8 (en)	2011-04-28
AU2007297212B2 (en)	2011-04-14
CA2663401A1 (en)	2008-03-20
AP2009004790A0 (en)	2009-04-30
WO2008032162A1 (en)	2008-03-20
CU20090040A7 (es)	2011-07-11
WO2008032162A8 (en)	2009-03-26
JP2010503653A (ja)	2010-02-04
DK2074122T3 (da)	2011-08-15
EA016388B1 (ru)	2012-04-30
GT200700077A (es)	2009-08-03
KR20090040389A (ko)	2009-04-23
RS51927B (en)	2012-02-29
MY146420A (en)	2012-08-15
EP2074122A1 (en)	2009-07-01
RS20090104A (en)	2010-06-30
BRPI0716749B1 (pt)	2020-10-06
HK1138589A1 (en)	2010-08-27
IL197243A0 (en)	2009-12-24
HRP20110621T2 (hr)	2013-12-06
DOP2009000039A (es)	2015-12-15
UY30588A1 (es)	2008-05-02
US8633204B2 (en)	2014-01-21
AR062785A1 (es)	2008-12-03
BRPI0716749B8 (pt)	2021-05-25
CA2663401C (en)	2011-07-12
SI2074122T1 (sl)	2011-10-28
TWI334353B (en)	2010-12-11
CR10662A (es)	2009-04-17
EP2074122B1 (en)	2011-06-29

Publication	Publication Date	Title
BRPI0716749A2 (pt)	2014-02-18	Compostos pirido (2,3-d) pirimidinona e seu uso como inibidores pi3
BRPI0817681A2 (pt)	2015-04-14	Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase
DK2004654T3 (da)	2013-07-22	Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
SMT201500120B (it)	2015-07-09	Agenti di legame di notch e antagonisti di notch emetodi per il loro uso
DK1926722T3 (da)	2011-12-19	Substituerede benzimidazoler som kinaseinhibitorer
BRPI0813831A2 (pt)	2015-01-06	Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
CR10369A (es)	2009-01-09	Pyrimidine derivatives as pi3k inhibitors
SMAP201000104A (it)	2010-11-12	Pirrolo[2,3-D]piridine e loro uso come inibitori di tirosina chinasi.
DK2118101T3 (da)	2013-01-02	IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer
BRPI0815979A2 (pt)	2017-06-13	compostos e composições com inibidores de quinase, bem como uso dos mesmos
DK2201012T3 (da)	2014-09-08	Pyrrolo[2,3-d]pyrimidinderivater som proteinkinase b-hæmmere
IL197231A0 (en)	2009-12-24	Pyrimidines derivatives and their use as kinase inhibitors
BRPI0810523A2 (pt)	2014-10-21	Derivado heterocíclico de 5 membros e uso do mesmo para propósitos médicos.
DK1761505T3 (da)	2011-12-05	Pyrimidin-urinstof-derivater som kinaseinhibitorer
DK2137184T3 (da)	2013-07-22	Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer
SMP200800029B (it)	2008-05-07	2-ammino-7,8-diidro-6h-pirido[4,3-d]pirimidin-5-oni
DK2124944T3 (da)	2012-04-23	Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
BRPI0808172A2 (pt)	2014-11-04	Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
BRPI0813587A2 (pt)	2014-12-30	Composto, uso do mesmo, e, composição farmacêutica
SI2004654T1 (sl)	2013-11-29	Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
BRPI0817044A2 (pt)	2015-03-24	Compostos de nicotinamida substituída e seu uso em medicamentos
ATE435865T1 (de)	2009-07-15	Als pde5-inhibitoren verwendete pyrazoloä4,3- düpyrimidin-5-ylderivate
BRPI0812535A2 (pt)	2017-05-16	derivado de 17beta-ciano-19-androst-4-eno, seu uso e medicamentos compreendendo o derivado
ATE489386T1 (de)	2010-12-15	Naphthyridin-derivate
BRPI0816158A2 (pt)	2017-06-13	composto carbociclo fundido substituído com heterociclila e uso do mesmo.

Legal Events

Date	Code	Title	Description
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-30	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2018-12-04	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-05-19	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-06-16	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-10-06	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2022-06-28	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 15A ANUIDADE.
2022-10-25	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2686 DE 28-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.